scholarly journals DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES

2009 ◽  
Vol 12 (7) ◽  
pp. A234
Author(s):  
R Goeree ◽  
ME Lim ◽  
R Hopkins ◽  
G Blackhouse ◽  
JE Tarride ◽  
...  
Keyword(s):  
Disease Modeling ◽  
Population Based ◽  
Potential Bias ◽  
Risk Estimates ◽  
Complication Risk ◽  
Disease Specific

Disease‐specific hospitalizations among 5‐year survivors of Wilms tumor: A Nordic population‐based cohort study

2021 ◽  
Author(s):  
Stine Høgsholt ◽  
Peter Haubjerg Asdahl ◽  
Trine Gade Bonnesen ◽  
Anna Sällfors Holmqvist ◽  
Laura Madanat‐Harjuoja ◽  
...  
Keyword(s):  
Cohort Study ◽  
Wilms Tumor ◽  
Population Based ◽  
Disease Specific

scholarly journals The Promise of Human Induced Pluripotent Stem Cells in Dental Research

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Thekkeparambil Chandrabose Srijaya ◽  
Padmaja Jayaprasad Pradeep ◽  
Rosnah Binti Zain ◽  
Sabri Musa ◽  
Noor Hayaty Abu Kasim ◽  
...  
Keyword(s):  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Disease Modeling ◽  
Patient Specific ◽  
Dental Research ◽  
Cell Based Therapy ◽  
Induced Pluripotent ◽  
Disease Specific

Induced pluripotent stem cell-based therapy for treating genetic disorders has become an interesting field of research in recent years. However, there is a paucity of information regarding the applicability of induced pluripotent stem cells in dental research. Recent advances in the use of induced pluripotent stem cells have the potential for developing disease-specific iPSC linesin vitrofrom patients. Indeed, this has provided a perfect cell source for disease modeling and a better understanding of genetic aberrations, pathogenicity, and drug screening. In this paper, we will summarize the recent progress of the disease-specific iPSC development for various human diseases and try to evaluate the possibility of application of iPS technology in dentistry, including its capacity for reprogramming some genetic orodental diseases. In addition to the easy availability and suitability of dental stem cells, the approach of generating patient-specific pluripotent stem cells will undoubtedly benefit patients suffering from orodental disorders.

scholarly journals Factors Influencing Risk of Premature Mortality in Community Cases of Depression: A Meta-Analytic Review

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Amanda J. Baxter ◽  
Andrew Page ◽  
Harvey A. Whiteford
Keyword(s):  
Systematic Review ◽  
Relative Risk ◽  
Excess Mortality ◽  
Depressive Disorders ◽  
Meta Analysis ◽  
Premature Mortality ◽  
Population Based ◽  
Clinical Depression ◽  
Risk Estimates ◽  
Significant Difference

Background. Depressive disorders are associated with substantial risk of premature mortality. A number of factors may contribute to reported risk estimates, making it difficult to determine actual risk of excess mortality in community cases of depression. The aim of this study is to conduct a systematic review and meta-analysis of excess mortality in population-based studies of clinically defined depression. Methods. Population-based studies reporting all-cause mortality associated with a clinically defined depressive disorder were included in the systematic review. Estimates of relative risk for excess mortality in population-representative cases of clinical depressive disorders were extracted. A meta-analysis was conducted using Stata to pool estimates of excess mortality and identify sources of heterogeneity within the data. Results. Twenty-one studies reporting risk of excess mortality in clinical depression were identified. A significantly higher risk of mortality was found for major depression (RR 1.92 95% CI 1.65–2.23), but no significant difference was found for dysthymia (RR 1.37 95% CI 0.93–2.00). Relative risk of excess mortality was not significantly different following the adjustment of reported risk estimates. Conclusion. A mortality gradient was identified with increasing severity of clinical depression. Recognition of depressive symptoms in general practice and appropriate referral for evidence-based treatment may help improve outcomes, particularly in patients with comorbid physical disorders.

Germ cell cancer (GCC): Long-term survival after treatment with bleomycin (B), etoposide (E), and cisplatin (P) in a large cohort.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4533-4533 ◽  
Author(s):  
Maria Gry Gundgaard ◽  
Jakob Lauritsen ◽  
Mette Sakso Mortensen ◽  
Mads Agerbaek ◽  
Niels Vilstrup Holm ◽  
...  
Keyword(s):  
Overall Survival ◽  
Germ Cell ◽  
Standard Treatment ◽  
Cell Cancer ◽  
Population Based ◽  
Germ Cell Cancer ◽  
Disease Specific Survival ◽  
Vital Status ◽  
Prognostic Group ◽  
Disease Specific

4533 Background: In 1997 the International Germ Cell Cancer Collaborative Group presented a classification dividing patients into a good, intermediate, and poor prognostic group for metastatic GCC with 5-year survival information. However, only a minor part of these patients were treated with today’s standard treatment. We present the first nationwide and population based study of overall survival (OS) and disease specific survival (DSS) in a large cohort of GCC patients treated with BEP. Methods: A nationwide and population based clinical database covering GCC patients diagnosed 1984-2007 was constructed, including 4,683 GCC cases. Through merging with national administrative registers, information on vital status and cause of death for all patients until November 30, 2012, was obtained. Results: The 5-year OS for the whole database cohort was 96%. A total of 1,584 patients were treated with BEP (1,099 patients with primary metastatic disease, 485 patients relapsed from stage I). Until 2001, the standard treatment was 4 cycles of BEP, after 2001 patients with good prognosis had 3 cycles of BEP. Overall survival (OS) and disease specific survival (DSS) with 95% confidence intervals (95% CI) (Table), median observation time was 13.8 years. Conclusions: This cohort study showed improved OS for GCC patients across all prognostic groups since 1997, in particular regarding the poor prognostic group. The present result is based on a large number of cases established in a population based fashion, with long follow up time and unbiased information covering all cohort members including detailed clinical information and vital status of all patients. [Table: see text]

Quality of care for medical comorbidities among patients with and without schizophrenia

2016 ◽  
Vol 33 (S1) ◽  
pp. s255-s255
Author(s):  
M. Jørgensen ◽  
J. Mainz ◽  
S. Paaske Johnsen
Keyword(s):  
Heart Failure ◽  
Quality Of Care ◽  
Beta Blockers ◽  
Population Based ◽  
Chronic Obstructive ◽  
Diabetic Patients ◽  
Medical Comorbidities ◽  
Processes Of Care ◽  
Disease Specific

IntroductionThe association between schizophrenia and quality of care for medical comorbidities in universal health care systems remains unclear.ObjectivesTo elucidate whether equal access also implies equivalent and sufficient care.AimsTo compare the quality of care for heart failure, diabetes and chronic obstructive pulmonary disease (COPD) among patients with and without schizophrenia in Denmark.MethodsIn a nationwide population-based cohort study, we used Danish national registries to estimate the risk of receiving guideline recommended disease-specific processes of care between 2004 and 2013.ResultsCompared to patients without schizophrenia, patients with schizophrenia had lower chance of receiving high overall quality of care (≥ 80% of recommended processes of care) for heart failure (Relative risk [RR] 0.67, 95% CI: 0.48-0.92), diabetes (RR 0.84, 95% CI: 0.79-0.89) and COPD (RR 0.82, 95% CI: 0.72-0.93) as well as lower chance of receiving individual disease-specific processes of care including treatment with beta-blockers (RR 0.87, 95% CI: 0.79-0.96) in heart failure care and measurement for albuminuria (RR 0.96, 95% CI: 0.93-0.99), eye examination at least every second year (RR 0.97, 95% CI: 0.94-0.99) and feet examination (RR 0.96, 95% CI: 0.93-0.99) in diabetes care. Diabetic patients with schizophrenia also had lower chance of receiving antihypertensive (RR 0.84, 95% CI: 0.73-0.96) and ACE/ATII inhibitors (RR 0.72, 95% CI: 0.55-0.94). In COPD care, patients with schizophrenia had lower chance of receiving LAMA/LABA medication (RR 0.92, 95% CI: 0.87-0.98), however, higher chance of treatment with non-invasive inhalation (RR 1.85, 95% CI: 1.61-2.12).ConclusionsQuality of care for three medical comorbidities was suboptimal for patients with schizophrenia.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Disease-specific mortality among stage I–III colorectal cancer patients with diabetes: a large population-based analysis

Diabetologia ◽  
2012 ◽  
Vol 55 (8) ◽  
pp. 2163-2172 ◽  
Author(s):  
L. V. van de Poll-Franse ◽  
H. R. Haak ◽  
J. W. W. Coebergh ◽  
M. L. G. Janssen-Heijnen ◽  
V. E. P. P. Lemmens
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Large Population ◽  
Population Based ◽  
Stage I ◽  
Specific Mortality ◽  
Patients With Diabetes ◽  
Disease Specific Mortality ◽  
Colorectal Cancer Patients ◽  
Disease Specific
Sign in / Sign up

Export Citation Format

Share Document